Nanotechnology in Pediatric Neurology: Applications and Innovations.
This review summarizes nanomaterials, smart delivery systems, theranostics, and emerging computational or organoid-based approaches for pediatric neurological diseases, including pediatric brain tumors, while emphasizing developmental pharmacology, safety, regulatory, and translational challenges.
Open original publication →What the AI sees
This review summarizes nanomaterials, smart delivery systems, theranostics, and emerging computational or organoid-based approaches for pediatric neurological diseases, including pediatric brain tumors, while emphasizing developmental pharmacology, safety, regulatory, and translational challenges.
Research significance
The review reports that nanocarriers may improve barrier penetration, targeted delivery, and treatment monitoring in pediatric neurological conditions; it is an inference—not demonstrated clinical evidence in this record—that age-adjusted, tumor-targeted nanoplatforms could improve pediatric brain-tumor treatment efficacy or reduce toxicity.
Source abstract
Nanotechnology is rapidly transforming the perspective on pediatric neurology, enabling diagnostic, therapeutic, and monitoring strategies tailored to the unique features of neurological illnesses in children. This review acknowledges the problems caused by delays in diagnosis, the limitations of conventional procedures, and the need for new, focused approaches, highlighting recent advances in nanoscale materials and smart nanocarriers. Specifically, this paper summarizes advances in nanomaterials that can overcome physiological barriers, such as the developing blood-brain barrier (BBB) and age-dependent pharmacokinetics. We discuss innovations in stimuli-responsive delivery systems, theranostic platforms, and multimodal nanohybrids designed for precise targeting and real-time treatment monitoring. Special emphasis is placed on pediatric-specific considerations, including developmental differences in immune and metabolic responses, the necessity for age-adjusted dosing, and the potential long-term safety implications of nanoparticle exposure. Transformative applications are explored in various pediatric neurological conditions, including brain tumors, epilepsy, neurodevelopmental disorders, and rare degenerative diseases, emphasizing both achievements and challenges in translation. This paper evaluates various regulatory, ethical, and societal factors, alongside the integration of converging technologies such as AI-driven nanoparticle optimization, brain organoids, and digital twins to accelerate personalized therapy development. Conclusively, this paper emphasizes the importance of interdisciplinary collaboration, pediatric-focused clinical trial designs, and sustained investment to fully realize the potential of nanotechnology in improving neurological outcomes for children.